AMG 355 + pembrolizumab

This combination drug consists of **AMG 355**, a novel investigational anti-CCR8 monoclonal antibody, administered with **pembrolizumab**, an FDA-approved anti-PD-1 monoclonal antibody (marketed as Keytruda). AMG 355 is designed to enhance antitumor immunity by targeting and depleting regulatory T cells (Tregs) in the tumor microenvironment, specifically those expressing the chemokine receptor CCR8, aiming to reduce local immunosuppression. Pembrolizumab blocks the PD-1 pathway, releasing the brake on immune effector T cells to improve their ability to attack cancer cells. The combination is under clinical development for advanced solid tumors to evaluate potential synergistic antitumor effects through dual immune modulation[1][3][4][7][8][9].

Brand names

Keytruda

Other names

anti-CCR8 monoclonal antibody + pembrolizumab